title: DNA microarray in search of new drug targets for myasthenia gravis.
abstract: DNA microarray technology was used to identify new potential drug targets for myasthenia gravis (MG), to delineate genes involved in the pathogenesis of the disease and to possibly target their protein products for immunotherapy. In this study we compared the gene expression in lymph node cells (LNC) and muscles of rats with experimental autoimmune MG (EAMG) to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG, we chose to elaborate on two gene systems: (a) The chemokine IFN-gamma-inducible protein 10 (IP-10, CXCL10), and its receptor (CXCR3) and (b) phosphodiesterases.
authors.affiliation: Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel.
authors.forename: Tali
authors.initials: T
authors.lastname: Feferman
authors.forename: Revital
authors.initials: R
authors.lastname: Aricha
authors.forename: Renuka
authors.initials: R
authors.lastname: Menon
authors.forename: Miriam C
authors.initials: MC
authors.lastname: Souroujon
authors.forename: Sonia
authors.initials: S
authors.lastname: Berrih-Aknin
authors.forename: Sara
authors.initials: S
authors.lastname: Fuchs
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D054357:Chemokine CXCL10; D019743:Chemokines, CXC / Q000235:genetics; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005786:Gene Expression Regulation; D006801:Humans; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine / Q000235:genetics